Michael Benatar

List of Publications by Year
in descending order

149 papers	16,633 citations	31976 53 h-index	16650 123 g-index
161 all docs	161 docs citations	161 times ranked	15582 citing authors

#	Article	IF	Citations
1	A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD. Neuron, 2011, 72, 257-268.	8.1	3,833
2	Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature, 2013, 495, 467-473.	27.8	1,249
3	Exome Sequencing Reveals VCP Mutations as a Cause of Familial ALS. Neuron, 2010, 68, 857-864.	8.1	1,100
4	International consensus guidance for management of myasthenia gravis. Neurology, 2016, 87, 419-425.	1.1	736
5	Randomized Trial of Thymectomy in Myasthenia Gravis. New England Journal of Medicine, 2016, 375, 511-522.	27.0	695
6	Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 153-174.	1.7	607
7	Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron, 2018, 97, 1268-1283.e6.	8.1	517
8	Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurology, The, 2017, 16, 976-986.	10.2	472
9	Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurology, The, 2013, 12, 310-322.	10.2	454
10	Lost in translation: Treatment trials in the SOD1 mouse and in human ALS. Neurobiology of Disease, 2007, 26, 1-13.	4.4	322
11	International Consensus Guidance for Management of Myasthenia Gravis. Neurology, 2021, 96, 114-122.	1.1	272
12	A systematic review of diagnostic studies in myasthenia gravis. Neuromuscular Disorders, 2006, 16, 459-467.	0.6	232
13	Rituximab as treatment for anti-MuSK myasthenia gravis. Neurology, 2017, 89, 1069-1077.	1.1	185
14	Neurofilament light: A candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Annals of Neurology, 2018, 84, 130-139.	5.3	182
15	Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72 -associated amyotrophic lateral sclerosis. Science Translational Medicine, 2017, 9, .	12.4	179
16	Longâ€term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle and Nerve, 2019, 60, 14-24.	2.2	162
17	Evidence-based guideline summary: Evaluation, diagnosis, and management of facioscapulohumeral muscular dystrophy. Neurology, 2015, 85, 357-364.	1.1	157
18	Towards a neuroimaging biomarker for amyotrophic lateral sclerosis. Lancet Neurology, The, 2011, 10, 400-403.	10.2	156

#	Article	IF	Citations
19	A Genome-Wide Association Study of Myasthenia Gravis. JAMA Neurology, 2015, 72, 396.	9.0	139
20	Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial. Lancet Neurology, The, 2019, 18, 259-268.	10.2	139
21	Evidence report: The medical treatment of ocular myasthenia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology [RETIRED]. Neurology, 2007, 68, 2144-2149.	1.1	132
22	Methodological Quality of Animal Studies of Neuroprotective Agents Currently in Phase II/III Acute Ischemic Stroke Trials. Stroke, 2009, 40, 577-581.	2.0	125
23	Electrical impedance myography as a biomarker to assess ALS progression. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 439-445.	2.1	125
24	Recommendations for myasthenia gravis clinical trials. Muscle and Nerve, 2012, 45, 909-917.	2.2	122
25	Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. Neurology, 2020, 95, e59-e69.	1.1	119
26	Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): A randomized, controlled trial. Muscle and Nerve, 2016, 53, 363-369.	2.2	113
27	Novel mutations expand the clinical spectrum of DYNC1H1 -associated spinal muscular atrophy. Neurology, 2015, 84, 668-679.	1.1	106
28	A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis. Neurology, 2016, 87, 57-64.	1.1	106
29	Utility of axial and radial diffusivity from diffusion tensor MRI as markers of neurodegeneration in amyotrophic lateral sclerosis. Brain Research, 2010, 1348, 156-164.	2.2	105
30	Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials. Neurology, 2019, 92, e1610-e1623.	1.1	105
31	Exome sequencing in amyotrophic lateral sclerosis implicates a novel gene, DNAJC7, encoding a heat-shock protein. Nature Neuroscience, 2019, 22, 1966-1974.	14.8	101
32	Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive SOD1 ALS. Neurology, 2018, 90, e565-e574.	1.1	99
33	HIV neuropathy in South Africans: Frequency, characteristics, and risk factors. Muscle and Nerve, 2010, 41, 599-606.	2.2	98
34	Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis. Neurology, 2021, 96, e853-e865.	1.1	97
35	Presymptomatic studies in ALS. Neurology, 2012, 79, 1732-1739.	1.1	94
36	Phosphorylated neurofilament heavy chain: A biomarker of survival for <scp>C9ORF</scp>72â€associated amyotrophic lateral sclerosis. Annals of Neurology, 2017, 82, 139-146.	5.3	88

#	Article	IF	Citations
37	Valosin-containing protein (VCP) mutations in sporadic amyotrophic lateral sclerosis. Neurobiology of Aging, 2012, 33, 2231.e1-2231.e6.	3.1	86
38	Motor neuron involvement in multisystem proteinopathy. Neurology, 2013, 80, 1874-1880.	1.1	85
39	ALS biomarkers for therapy development: State of the field and future directions. Muscle and Nerve, 2016, 53, 169-182.	2.2	85
40	Urinary p75 ^{ECD}. Neurology, 2017, 88, 1137-1143.	1.1	84
41	Increased functional connectivity common to symptomatic amyotrophic lateral sclerosis and those at genetic risk. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 580-588.	1.9	82
42	Diffusion tensor imaging reveals regional differences in the cervical spinal cord in amyotrophic lateral sclerosis. NeuroImage, 2010, 53, 576-583.	4.2	77
43	Neurofilaments in pre-symptomatic ALS and the impact of genotype. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 538-548.	1.7	76
44	Repeat expansions in the C9ORF72 gene contribute to Alzheimer's disease in Caucasians. Neurobiology of Aging, 2013, 34, 1519.e5-1519.e12.	3.1	74
45	Concentric-needle single-fiber electromyography for the diagnosis of myasthenia gravis. Muscle and Nerve, 2006, 34, 163-168.	2.2	73
46	Diagnostic Accuracy of Diffusion Tensor Imaging in Amyotrophic Lateral Sclerosis. Academic Radiology, 2013, 20, 1099-1106.	2.5	70
47	C9ORF72 Intermediate Repeat Copies Are a Significant Risk Factor for Parkinson Disease. Annals of Human Genetics, 2013, 77, 351-363.	0.8	69
48	Treatment of ocular symptoms in myasthenia gravis. Neurology, 2008, 71, 1335-1341.	1.1	67
49	Enhancing translation: Guidelines for standard pre-clinical experiments in mdx mice. Neuromuscular Disorders, 2012, 22, 43-49.	0.6	67
50	Mind the gap: The mismatch between clinical and imaging metrics in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 524-529.	1.7	65
51	Enteral tube feeding for amyotrophic lateral sclerosis/motor neuron disease. The Cochrane Library, 2011, , CD004030.	2.8	63
52	Electrical impedance myography correlates with standard measures of Als severity. Muscle and Nerve, 2014, 49, 441-443.	2.2	61
53	Altered cortical betaâ€band oscillations reflect motor system degeneration in amyotrophic lateral sclerosis. Human Brain Mapping, 2017, 38, 237-254.	3.6	58
54	Dipeptide repeat proteins inhibit homology-directed DNA double strand break repair in C9ORF72 ALS/FTD. Molecular Neurodegeneration, 2020, 15, 13.	10.8	58

#	Article	IF	Citations
55	Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravis. Muscle and Nerve, 2019, 59, 404-410.	2.2	56
56	Sural and radial sensory responses in healthy adults: Diagnostic implications for polyneuropathy. Muscle and Nerve, 2005, 31, 628-632.	2.2	55
57	ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis. Frontiers in Neurology, 2019, 10, 293.	2.4	54
58	Defining pre-symptomatic amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 303-309.	1.7	53
59	Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis. Neurology, 2022, 98, .	1.1	51
60	Ocular Myasthenia. Neurologic Clinics, 2018, 36, 241-251.	1.8	50
61	Ensuring continued progress in biomarkers for amyotrophic lateral sclerosis. Muscle and Nerve, 2015, 51, 14-18.	2.2	48
62	Reference data for commonly used sensory and motor nerve conduction studies. Muscle and Nerve, 2009, 40, 772-794.	2.2	47
63	Magnetic resonance spectroscopy of the cervical cord in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2011, 12, 185-191.	2.1	47
64	Presymptomatic ALS genetic counseling and testing. Neurology, 2016, 86, 2295-2302.	1.1	47
65	Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study. Neurotherapeutics, 2022, 19, 1248-1258.	4.4	46
66	Efficacy and Tolerability of Levetiracetam in Children Younger than 4 Years: A Retrospective Review. Epilepsia, 2007, 48, 1123-1127.	5.1	40
67	Accuracy of repetitive nerve stimulation for diagnosis of the crampâ€“fasciculation syndrome. Muscle and Nerve, 2007, 35, 776-780.	2.2	38
68	Progress towards a neuroimaging biomarker for amyotrophic lateral sclerosis. Lancet Neurology, The, 2015, 14, 786-788.	10.2	38
69	Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases. Brain, 2022, 145, 27-44.	7.6	38
70	Reducing sample size requirements for future ALS clinical trials with a dedicated electrical impedance myography system. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 555-561.	1.7	37
71	The electromyographic diagnosis of amyotrophic lateral sclerosis: Does the evidence support the El Escorial criteria?. Muscle and Nerve, 2007, 35, 614-619.	2.2	36
72	Thymectomy for non-thymomatous myasthenia gravis. The Cochrane Library, 2013, , CD008111.	2.8	36

#	Article	IF	Citations
73	Impaired corticomuscular and interhemispheric cortical beta oscillation coupling in amyotrophic lateral sclerosis. Clinical Neurophysiology, 2018, 129, 1479-1489.	1.5	36
74	Impact of presymptomatic genetic testing for familial amyotrophic lateral sclerosis. Genetics in Medicine, 2011, 13, 342-348.	2.4	31
75	Mutational analysis of the VCP gene in Parkinson's disease. Neurobiology of Aging, 2012, 33, 209.e1-209.e2.	3.1	31
76	Pediatric Cancer Variant Pathogenicity Information Exchange (PeCanPIE): a cloud-based platform for curating and classifying germline variants. Genome Research, 2019, 29, 1555-1565.	5.5	28
77	Repetitive nerve stimulation for the evaluation of peripheral nerve hyperexcitability. Journal of the Neurological Sciences, 2004, 221, 47-52.	0.6	26
78	Design of the Efficacy of Prednisone in the Treatment of Ocular Myasthenia (EPITOME) trial. Annals of the New York Academy of Sciences, 2012, 1275, 17-22.	3.8	26
79	Increased cerebral functional connectivity in ALS. Neurology, 2018, 90, e1418-e1424.	1.1	26
80	CSF chitinases before and after symptom onset in amyotrophic lateral sclerosis. Annals of Clinical and Translational Neurology, 2020, 7, 1296-1306.	3.7	26
81	Levetiracetam Versus Carbamazepine Monotherapy for Partial Epilepsy in Children Less Than 16 Years of Age. Journal of Child Neurology, 2008, 23, 515-519.	1.4	25
82	Bromodomain inhibitors regulate the C9ORF72 locus in ALS. Experimental Neurology, 2015, 271, 241-250.	4.1	25
83	Medical and surgical treatment for ocular myasthenia. The Cochrane Library, 2017, 2017, CD005081.	2.8	24
84	Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine. Muscle and Nerve, 2016, 53, 165-168.	2.2	24
85	Getting Rid of Weakness in the ICU: An Updated Approach to the Acute Management of Myasthenia Gravis and Guillain-BarrÃ© Syndrome. Seminars in Neurology, 2016, 36, 615-624.	1.4	23
86	The Spectrum of Cranial Neuropathy in Patients With Bellâ€™s Palsy. Archives of Internal Medicine, 2004, 164, 2383.	3.8	22
87	Medical and surgical treatment for ocular myasthenia. , 2006, , CD005081.		22
88	Outcome Analysis in Clinical Trial Design for Acute Stroke: Physiciansâ€™ Attitudes and Choices. Cerebrovascular Diseases, 2008, 26, 156-162.	1.7	22
89	A C9ORF72 BAC mouse model recapitulates key epigenetic perturbations of ALS/FTD. Molecular Neurodegeneration, 2017, 12, 46.	10.8	22
90	Utility of Capture-Recapture Methodology to Assess Completeness of Amyotrophic Lateral Sclerosis Case Ascertainment. Neuroepidemiology, 2013, 40, 133-141.	2.3	21

#	Article	IF	Citations
91	C9orf72 promoter hypermethylation is reduced while hydroxymethylation is acquired during reprogramming of ALS patient cells. Experimental Neurology, 2016, 277, 171-177.	4.1	21
92	The muddle of mycophenolate mofetil in myasthenia. Neurology, 2008, 71, 390-391.	1.1	20
93	Developing reference data for nerve conduction studies: An application of quantile regression. Muscle and Nerve, 2009, 40, 763-771.	2.2	20
94	Immune-mediated peripheral neuropathies and voltage-gated sodiums channels. , 1999, 22, 108-110.		19
95	Preventing familial amyotrophic lateral sclerosis: Is a clinical trial feasible?. Journal of the Neurological Sciences, 2006, 251, 3-9.	0.6	19
96	ALS Untangled No. 20: The Deanna Protocol. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 319-323.	1.7	19
97	The Awaji criteria for the diagnosis of amyotrophic lateral sclerosis: Have we put the cart before the horse?. Muscle and Nerve, 2011, 43, 461-463.	2.2	17
98	Sequence variations in C9orf72 downstream of the hexanucleotide repeat region and its effect on repeat-primed PCR interpretation: a large multinational screening study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 256-264.	1.7	17
99	Mild motor impairment as prodromal state in amyotrophic lateral sclerosis: a new diagnostic entity. Brain, 2022, 145, 3500-3508.	7.6	17
100	Clinical subtypes of anterocollis in parkinsonian syndromes. Journal of the Neurological Sciences, 2012, 315, 100-103.	0.6	16
101	Phase <scp>2B</scp> randomized controlled trial of <scp>NP001</scp> in amyotrophic lateral sclerosis: Preâ€specified and post hoc analyses. Muscle and Nerve, 2022, 66, 39-49.	2.2	16
102	Identification of compound heterozygous variants in OPTN in an ALS-FTD patient from the CReATe consortium: a case report. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 469-471.	1.7	15
103	The state of clinical research in neurology. Neurology, 2018, 90, e1347-e1354.	1.1	14
104	Urinary neopterin: A novel biomarker of disease progression in amyotrophic lateral sclerosis. European Journal of Neurology, 2022, 29, 990-999.	3.3	14
105	Diagnostic Accuracy of Thoracic Paraspinal Electromyography in Amyotrophic Lateral Sclerosis. Journal of Clinical Neurophysiology, 2007, 24, 298-300.	1.7	13
106	Machine learning suggests polygenic risk for cognitive dysfunction in amyotrophic lateral sclerosis. EMBO Molecular Medicine, 2021, 13, e12595.	6.9	13
107	Defining cognitive impairment in amyotrophic lateral sclerosis: an evaluation of empirical approaches. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 517-526.	1.7	13
108	Electrodiagnostic criteria for carpal tunnel syndrome in axonal polyneuropathy. Muscle and Nerve, 2006, 33, 747-752.	2.2	12

#	Article	IF	Citations
109	Clinical Equipoise and Treatment Decisions in Cervical Spondylotic Myelopathy. Canadian Journal of Neurological Sciences, 2007, 34, 47-52.	0.5	12
110	Treatment of Pyridostigmine-Induced AV Block with Hyoscyamine in a Patient with Myasthenia Gravis. Journal of Cardiovascular Electrophysiology, 2008, 19, 214-216.	1.7	12
111	Abnormal expression of homeobox genes and transthyretin in C9ORF72 expansion carriers. Neurology: Genetics, 2017, 3, e161.	1.9	12
112	Epidemiological evidence for a hereditary contribution to myasthenia gravis: a retrospective cohort study of patients from North America. BMJ Open, 2020, 10, e037909.	1.9	12
113	SELECTING PROMISING ALS THERAPIES IN CLINICAL TRIALS. Neurology, 2007, 68, 1545-1546.	1.1	11
114	Learning from the past: reflections on recently completed myasthenia gravis trials. Annals of the New York Academy of Sciences, 2018, 1412, 5-13.	3.8	11
115	An endogenous peptide marker differentiates SOD1 stability and facilitates pharmacodynamic monitoring in SOD1 amyotrophic lateral sclerosis. JCI Insight, 2019, 4, .	5.0	11
116	Pre-symptomatic spinal muscular atrophy: a proposed nosology. Brain, 2022, 145, 2247-2249.	7.6	11
117	Revealing the Mutational Spectrum in Southern Africans With Amyotrophic Lateral Sclerosis. Neurology: Genetics, 2022, 8, e654.	1.9	10
118	Preparing for a U.S. National ALS Registry: Lessons from a pilot project in the State of Georgia. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2011, 12, 130-135.	2.1	9
119	How clinical trials of myasthenia gravis can inform pre-clinical drug development. Experimental Neurology, 2015, 270, 78-81.	4.1	9
120	Yes, we can: Neuromuscular examination by telemedicine. Muscle and Nerve, 2020, 62, E83-E85.	2.2	9
121	Humoral response to neurofilaments and dipeptide repeats in ALS progression. Annals of Clinical and Translational Neurology, 2021, 8, 1831-1844.	3.7	8
122	Familial hemiplegic migraine: More than just a headache. Neurology, 2005, 64, 592-593.	1.1	7
123	Exome Sequencing Reveals VCP Mutations as a Cause of Familial ALS. Neuron, 2011, 69, 397.	8.1	7
124	FGF23, a novel muscle biomarker detected in the early stages of ALS. Scientific Reports, 2021, 11, 12062.	3.3	7
125	Distal symmetric polyneuropathy: Limitations of the proposed case definition. Muscle and Nerve, 2006, 34, 131-134.	2.2	6
126	Opportunity and innovation in studying preâ€symptomatic amyotrophic lateral sclerosis. Muscle and Nerve, 2013, 47, 629-631.	2.2	6

#	Article	IF	Citations
127	Repeats expansions in ATXN2, NOP56, NIPA1 and ATXN1 are not associated with ALS in Africans. IBRO Neuroscience Reports, 2021, 10, 130-135.	1.6	6
128	An 18F-FDG PET study of cervical muscle in parkinsonian anterocollis. Journal of the Neurological Sciences, 2014, 340, 174-177.	0.6	5
129	A case of familial ALS due to multi-system proteinopathy 1 and Huntington disease. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 124-126.	1.7	5
130	Epigenetic Small Molecules Rescue Nucleocytoplasmic Transport and DNA Damage Phenotypes in C9ORF72 ALS/FTD. Brain Sciences, 2021, 11, 1543.	2.3	5
131	Treatment for familial amyotrophic lateral sclerosis/motor neuron disease. The Cochrane Library, 2009, , CD006153.	2.8	4
132	To travel or not to travel: The modern day struggle of the academic researcher. Annals of Neurology, 2015, 78, 667-669.	5.3	4
133	Challenges and opportunities for Multi-National Investigator-Initiated clinical trials for ALS: European and United States collaborations. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 419-425.	1.7	4
134	Application of a bioinformatic pipeline to RNA-seq data identifies novel virus-like sequence in human blood. G3: Genes, Genomes, Genetics, 2021, 11, .	1.8	4
135	Harnessing the power of the electronic health record for <scp>ALS</scp> research and quality improvement: <scp>CReATe CAPTUREâ€ALS</scp> and the <scp>ALS</scp> Toolkit. Muscle and Nerve, 2022, 65, 154-161.	2.2	4
136	Interferon beta-1a and beta-1b for treatment of multiple sclerosis. Lancet, The, 2002, 360, 1428.	13.7	3
137	What zebras and mice can teach us about familial ALS. Neuromuscular Disorders, 2007, 17, 671-672.	0.6	3
138	Incremental Gains in the Battle against ALS. New England Journal of Medicine, 2020, 383, 979-980.	27.0	3
139	Reply. Annals of Neurology, 2016, 79, 334-334.	5.3	2
140	Occupational lead exposure and survival with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2023, 24, 100-107.	1.7	2
141	Pearls: Myasthenia. Seminars in Neurology, 2010, 30, 035-037.	1.4	1
142	Reply. Muscle and Nerve, 2013, 47, 145-146.	2.2	1
143	How Neurologists and Neuro-Ophthalmologists Think. Journal of Neuro-Ophthalmology, 2016, 36, 4-5.	0.8	1
144	To Zoom or Not to Zoom: The Should I Travel Index Revisited during the Coronavirus Disease Pandemic. Annals of Neurology, 2021, 89, 1057-1058.	5.3	1

#	Article	IF	Citations
145	Radicava/Edaravone Findings in Biomarkers From Amyotrophic Lateral Sclerosis (REFINE-ALS). Neurology: Clinical Practice, 2021, 11, e472-e479.	1.6	1
146	Autoimmune Neurological Disease. Trends in Neurosciences, 1996, 19, 301-302.	8.6	0
147	Laminoplasty. Journal of Neurosurgery: Spine, 2004, 100, 399-400; author reply 400.	1.7	0
148	Editorial: We may need large trials to find treatments for neurodegenerative diseases. Clinical Trials, 2019, 16, 120-121.	1.6	0
149	Radicava/Edaravone Findings in Biomarkers From Amyotrophic Lateral Sclerosis (REFINE-ALS): Protocol and Study Design. Neurology: Clinical Practice, 2021, 11, e472-e479.	1.6	0